Hana Golan

Dr Hana Golan serves as the deputy director and the head of the day care service of the Pediatric Hematology Oncology division. She completed her medical degree at the Technion- Israel Institute of Technology and specialized in pediatrics and pediatric hemato-oncology at the Safra Children’s Hospital at the Sheba Medical Center. Dr. Golan has a special interest in treating children with Neuroblastoma and serves as the PI of the international HR ESIOP protocol in the department.

Main research areas:

• Isolation and characterization of cancer stem cells from various pediatric solid tumors
• Development of new treatments designed to target and destroy cancer stem cells.
• The effects of cannabinoids on pediatric tumors

TEACHING

• Coordinator of the Hematology course for medical students, Sackler Faculty of Medicine at Tel Aviv University, Israel, 2009-2011
• Pediatric Hematology oncology lectures for medical students and nurses, 1996 – Present.
• Tutor in charge of medical students, 1991-1992

PROJECTS

• Director of the computerized program of the inpatient and outpatient computerized medical record
• Establishment of computerized chemotherapy protocols and patient’s database, 1999 – ‏2014.

CLINICAL TRIALS EXPERIENCE

• Principle investigator of the High Risk Neuroblastoma 1.7 ESIOP protocol, Sheba medical center, 2002 – present.
• Principle investigator of the “Phase I/II, 2-part, Multi Center, Single arm, Open-Label Study, to determine the Safety, Tolerability and Pharmacokinetics of oral Dabrafenib in Children and Adolescent Subjects with Advanced BRAF V-600 Mutation Positive Solid Tumors. 2015-2016
• Principle investigator of the “Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder” 2013-2015
• National coordinator of the High Risk Neuroblastoma 1 ESIOP protocol, 2002 – 2005

Active involvement in several basic research programs including:

• Identification and isolation of cancer stem cells in pediatric malignancies in order to identify targetable markers (2 papers are currently in the processes of submission) The role of cannabinoids as anti-cancer drug in pediatric malignancies